Current treatment concepts of CML

Current Cancer Drug Targets

Volumn 11, Issue 1, 2011, Pages 31-43

  Leitner, A A ^a   Hochhaus, A ^b   Muller M C ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b JENA UNIVERSITY HOSPITAL   (Germany)

Author keywords

Bcr abl; Chronic myeloid leukemia; Dasatinib; Imatinib; Mutation; Nilotinib

Indexed keywords

AP 24534; BOSUTINIB; BUSULFAN; CYTARABINE; DASATINIB; HOMOHARRINGTONINE; HYDROXYUREA; IMATINIB; INTERFERON; NILOTINIB; PEGINTERFERON; PROTEIN TYROSINE KINASE INHIBITOR; TOZASERTIB; UNCLASSIFIED DRUG;

CANCER REGRESSION; CANCER SURVIVAL; CHROMOSOME ANALYSIS; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DIARRHEA; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG TREATMENT FAILURE; HUMAN; LEUKAPHERESIS; LOW DRUG DOSE; NAUSEA; PATIENT MONITORING; PLEURA EFFUSION; REVIEW; SURVIVAL RATE; VOMITING;

ANTINEOPLASTIC AGENTS; BLAST CRISIS; DRUG RESISTANCE, NEOPLASM; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES;

EID: 78951487732     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/156800911793743637     Document Type: Review

References (158)

1. Faderl, S.; Talpaz, M.; Estrov, Z.; O'Brien, S.; Kurzrock, R.; Kantarjian, H. M. The biology of chronic myeloid leukemia. N. Engl. J. Med. 1999, 341, 164-172.
2. Karanas, A.; Silver, R. T. Characteristics of the terminal phase of chronic granulocytic leukemia. Blood 1968, 32, 445-459.
3. Radich, J. P. The biology of CML blast crisis. Hematol. Am. Soc. Hematol. Educ. Program. 2007, 384-391.
4. O'Brien, S.; Berman, E.; Borghaei, H.; Deangelo, D. J.; Devetten, M. P.; Devine, S.; Erba, H. P.; Gotlib, J.; Jagasia, M.; Moore, J. O.; Mughal, T.; Pinilla-Ibarz, J.; Radich, J. P.; Shah Md, N. P.; Shami, P. J.; Smith, B. D.; Snyder, D. S.; Tallman, M. S.; Talpaz, M.; Wetzler, M. NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia. J. Natl. Compr. Canc. Netw. 2009, 7, 984-1023.
5. Vardiman, J. W.; Thiele, J.; Arber, D. A.; Brunning, R. D.; Borowitz, M. J.; Porwit, A.; Harris, N. L.; Le Beau, M. M.; Hellstrom-Lindberg, E.; Tefferi, A.; Bloomfield, C. D. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009, 114, 937-951.
6. Nowell, P. C.; Hungerford, D. A. A minute chromosome in human chronic granulocytic leukemia. Science 1960, 132, 1497-1501.
7. Nowell, P. C.; Hungerford, D. A. Chromosome studies in human leukemia. II. Chronic granulocytic leukemia. J. Natl. Cancer Inst. 1961, 27, 1013-1035.
8. Rowley, J. D. Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and giemsa staining. Nature 1973, 243, 290-293.
9. de Klein, A.; van Kessel, A. G.; Grosveld, G.; Bartram, C. R.; Hagemeijer, A.; Bootsma, D.; Spurr, N. K.; Heisterkamp, N.; Groffen, J.; Stephenson, J. R. A cellular oncogene is translocated to the philadelphia chromosome in chronic myelocytic leukaemia. Nature 1982, 300, 765-767.
10. Heisterkamp, N.; Stephenson, J. R.; Groffen, J.; Hansen, P. F.; de Klein, A.; Bartram, C. R.; Grosveld, G. Localization of the C-Ab1 oncogene adjacent to a translocation break point in chronic myelocytic leukaemia. Nature 1983, 306, 239-242.
11. Bartram, C. R.; de Klein, A.; Hagemeijer, A.; van Agthoven, T.; Geurts, v. K.; Bootsma, D.; Grosveld, G.; Ferguson-Smith, M. A.; Davies, T.; Stone, M. Translocation of C-Ab1 oncogene correlates with the presence of a philadelphia chromosome in chronic myelocytic leukaemia. Nature 1983, 306, 277-280.
12. Ben Neriah, Y.; Daley, G. Q.; Mes-Masson, A. M.; Witte, O. N.; Baltimore, D. The chronic myelogenous leukemia-specific P210 protein is the product of the Bcr/Abl hybrid gene. Science 1986, 233, 212-214.
13. Daley, G. Q.; Van Etten, R. A.; Baltimore, D. Induction of chronic myelogenous leukemia in mice by the P210bcr/Abl gene of the philadelphia chromosome. Science 1990, 247, 824-830.
14. Daley, G. Q.; Ben Neriah, Y. Implicating the Bcr/Abl gene in the pathogenesis of philadelphia chromosome-positive human leukemia. Adv. Cancer Res. 1991, 57, 151-184.
15. Ravandi, F.; Cortes, J.; Albitar, M.; Arlinghaus, R.; Qiang, G. J.; Talpaz, M.; Kantarjian, H. M. Chronic myelogenous leukaemia with P185(BCR/ABL) expression: characteristics and clinical significance. Br. J. Haematol. 1999, 107, 581-586.
16. van der Plas, D.C.; Grosveld, G.; Hagemeijer, A. Review of clinical, cytogenetic, and molecular aspects of ph-negative CML. Cancer Genet. Cytogenet. 1991, 52, 143-156.
17. Lugo, T. G.; Pendergast, A. M.; Muller, A. J.; Witte, O. N. Tyrosine kinase activity and transformation potency of Bcr-Abl oncogene products. Science 1990, 247, 1079-1082.
18. Gordon, M. Y.; Goldman, J. M. Cellular and molecular mechanisms in chronic myeloid leukaemia: biology and treatment. Br. J. Haematol. 1996, 95, 10-20.
19. Verfaillie, C. M. Chronic myelogenous leukemia: from pathogenesis to therapy. J. Hematother. 1999, 8, 3-13.
20. Lionberger, J. M.; Wilson, M. B.; Smithgall, T. E. Transformation of myeloid leukemia cells to cytokine independence by Bcr-Abl is suppressed by kinase-defective Hck. J. Biol. Chem. 2000, 275, 18581-18585.
21. Ptasznik, A.; Urbanowska, E.; Chinta, S.; Costa, M. A.; Katz, B. A.; Stanislaus, M. A.; Demir, G.; Linnekin, D.; Pan, Z. K.; Gewirtz, A. M. Crosstalk between BCR/ABL oncoprotein and CXCR4 signaling through a Src family kinase in human leukemia cells. J. Exp. Med. 2002, 196, 667-678.
22. Klejman, A.; Schreiner, S. J.; Nieborowska-Skorska, M.; Slupianek, A.; Wilson, M.; Smithgall, T. E.; Skorski, T. The Src family kinase Hck couples BCR/ABL to STAT5 activation in myeloid leukemia cells. EMBO J. 2002, 21, 5766-5774.
23. Stanglmaier, M.; Warmuth, M.; Kleinlein, I.; Reis, S.; Hallek, M. The interaction of the Bcr-Abl tyrosine kinase with the Src kinase Hck is mediated by multiple binding domains. Leukemia 2003, 17, 283-289.
24. Stamminger, G.; Koppel, C.; Schaub, A.; Gartner, I.; Tonndorf, C.; Meyer, K.; Elix, P.; Lang, B.; Beier, L. Performance of the SE-9000 automated haematology analyser in a laboratory serving a haematological oncology unit. Clin. Lab. Haematol. 1998, 20, 143-149.
25. Hehlmann, R.; Ansari, H.; Hasford, J.; Heimpel, H.; Hossfeld, D. K.; Kolb, H. J.; Loffler, H.; Pralle, H.; Queisser, W.; Reiter, A.; Hochhaus, A. Comparative analysis of the impact of risk profile and of drug therapy on survival in CML using sokal's index and a new score. German chronic myeloid leukaemia (CML)-study group. Br. J. Haematol. 1997, 97, 76-85.
26. Sokal, J. E.; Cox, E. B.; Baccarani, M.; Tura, S.; Gomez, G. A.; Robertson, J. E.; Tso, C. Y.; Braun, T. J.; Clarkson, B. D.; Cervantes, F. Prognostic discrimination in good-risk chronic granulocytic leukemia. Blood 1984, 63, 789-799.
27. Cotelingam, J. D. Bone marrow biopsy: interpretive guidelines for the surgical pathologist. Adv. Anat. Pathol. 2003, 10, 8-26.
28. Buesche, G.; Hehlmann, R.; Hecker, H.; Heimpel, H.; Heinze, B.; Schmeil, A.; Pfirrmann, M.; Gomez, G.; Tobler, A.; Herrmann, H.; Kappler, M.; Hasford, J.; Buhr, T.; Kreipe, H. H.; Georgii, A. Marrow fibrosis, indicator of therapy failure in chronic myeloid leukemia - prospective long-term results from a randomized-controlled trial. Leukemia 2003, 17, 2444-2453.
29. Buesche, G.; Freund, M.; Hehlmann, R.; Georgii, A.; Ganser, A.; Hecker, H.; Heimpel, H.; Fonatsch, C.; Heinze, B.; Pfirrmann, M.; Holgado, S.; Schmeil, A.; Tobler, A.; Hasford, J.; Buhr, T.; Kreipe, H. H. Treatment intensity significantly influencing fibrosis in bone marrow independently of the cytogenetic response: meta-analysis of the long-term results from two prospective controlled trials on chronic myeloid leukemia. Leukemia 2004, 18, 1460-1467.
30. Kantarjian, H. M.; Bueso-Ramos, C. E.; Talpaz, M.; O'Brien, S.; Giles, F.; Rios, M. B.; Shan, J.; Cortes, J. The degree of bone marrow fibrosis in chronic myelogenous leukemia is not a prognostic factor with imatinib mesylate therapy. Leuk. Lymphoma 2005, 46, 993-997.
31. Buesche, G.; Ganser, A.; Schlegelberger, B.; von Neuhoff, N.; Gadzicki, D.; Hecker, H.; Bock, O.; Frye, B.; Kreipe, H. Marrow fibrosis and its relevance during imatinib treatment of chronic myeloid leukemia. Leukemia 2007, 21, 2420-2427.
32. Baccarani, M.; Saglio, G.; Goldman, J.; Hochhaus, A.; Simonsson, B.; Appelbaum, F.; Apperley, J.; Cervantes, F.; Cortes, J.; Deininger, M.; Gratwohl, A.; Guilhot, F.; Horowitz, M.; Hughes, T.; Kantarjian, H.; Larson, R.; Niederwieser, D.; Silver, R.; Hehlmann, R. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the european leukemianet. Blood 2006, 108, 1809-1820.
33. Baccarani, M.; Cortes, J.; Pane, F.; Niederwieser, D.; Saglio, G.; Apperley, J.; Cervantes, F.; Deininger, M.; Gratwohl, A.; Guilhot, F.; Hochhaus, A.; Horowitz, M.; Hughes, T.; Kantarjian, H.; Larson, R.; Radich, J.; Simonsson, B.; Silver, R. T.; Goldman, J.; Hehlmann, R. Chronic myeloid leukemia: an update of concepts and management recommendations of european leukemianet. J. Clin. Oncol. 2009, 27, 6041-6051.
34. Hehlmann, R.; Hochhaus, A.; Baccarani, M. Chronic myeloid leukaemia. Lancet 2007, 370, 342-350.
35. Pavlovsky, C.; Kantarjian, H.; Cortes, J. E. First-line therapy for chronic myeloid leukemia: past, present, and future. Am. J. Hematol. 2009, 84, 287-293.
36. Johansson, B.; Fioretos, T.; Mitelman, F. Cytogenetic and molecular genetic evolution of chronic myeloid leukemia. Acta Haematol. 2002, 107, 76-94.
37. Marktel, S.; Marin, D.; Foot, N.; Szydlo, R.; Bua, M.; Karadimitris, A.; De, M., V; Kotzampaltiris, P.; Dazzi, F.; Rahemtulla, A.; Olavarria, E.; Apperley, J. F.; Goldman, J. M. Chronic myeloid leukemia in chronic phase responding to imatinib: the occurrence of additional cytogenetic abnormalities predicts disease progression. Haematologica 2003, 88, 260-267.
38. Aurer, I.; Canaani, E.; Gale, R. P. Hypothesis: additional cytogenetic abnormalities and progression to acute phase in chronic myelogenous leukemia. Leukemia 1991, 5, 1012-1013.
39. Farag, S. S.; Ruppert, A. S.; Mrozek, K.; Carroll, A. J.; Pettenati, M. J.; Le Beau, M. M.; Peterson, B. L.; Powell, B. L.; Ozer, H.; Silver, R. T.; Larson, R. A.; Bloomfield, C. D. Prognostic significance of additional cytogenetic abnormalities in newly diagnosed patients with philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha: a cancer and leukemia group B study. Int. J. Oncol. 2004, 25, 143-151.
40. Sokal, J. E.; Gomez, G. A.; Baccarani, M.; Tura, S.; Clarkson, B. D.; Cervantes, F.; Rozman, C.; Carbonell, F.; Anger, B.; Heimpel, H.;. Prognostic significance of additional cytogenetic abnormalities at diagnosis of philadelphia chromosome-positive chronic granulocytic leukemia. Blood 1988, 72, 294-298.
41. Akel, S.; Kolialexi, A.; Mavrou, A.; Metaxotou, C.; Loukopoulos, D.; Yataganas, X. Efficiency of interphase fluorescence in situ hybridization for BCR/ABL on peripheral blood smears for monitoring of CML patients: a comparison with bone marrow findings. Clin. Lab. Haematol. 2002, 24, 361-367.
42. Testoni, N.; Marzocchi, G.; Luatti, S.; Amabile, M.; Baldazzi, C.; Stacchini, M.; Nanni, M.; Rege-Cambrin, G.; Giugliano, E.; Giussani, U.; Abruzzese, E.; Kerim, S.; Grimoldi, M. G.; Gozzetti, A.; Crescenzi, B.; Carcassi, C.; Bernasconi, P.; Cuneo, A.; Albano, F.; Fugazza, G.; Zaccaria, A.; Martinelli, G.; Pane, F.; Rosti, G.; Baccarani, M. Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response, a study of the GIMEMA CML WP. Blood 2009, 114, 4939-4943.
43. Gadzicki, D.; von Neuhoff, N.; Steinemann, D.; Just, M.; Busche, G.; Kreipe, H.; Wilkens, L.; Schlegelberger, B. BCR-ABL gene amplification and overexpression in a patient with chronic myeloid leukemia treated with imatinib. Cancer Genet. Cytogenet. 2005, 159, 164-167.
44. Mühlmann, J.; Thaler, J.; Hilbe, W.; Bechter, O.; Erdel, M.; Utermann, G.; Duba, H. C. Fluorescence in situ hybridization (FISH) on peripheral blood smears for monitoring philadelphia chromo-some-positive chronic myeloid leukemia (CML) during interferon treatment: a new strategy for remission assessment. Genes Chromosomes. Cancer 1998, 21, 90-100.
45. Druker, B. J.; Guilhot, F.; O'Brien, S. G.; Gathmann, I.; Kantarjian, H.; Gattermann, N.; Deininger, M. W.; Silver, R. T.; Goldman, J. M.; Stone, R. M.; Cervantes, F.; Hochhaus, A.; Powell, B. L.; Gabrilove, J. L.; Rousselot, P.; Reiffers, J.; Cornelissen, J. J.; Hughes, T.; Agis, H.; Fischer, T.; Verhoef, G.; Shepherd, J.; Saglio, G.; Gratwohl, A.; Nielsen, J. L.; Radich, J. P.; Simonsson, B.; Taylor, K.; Baccarani, M.; So, C.; Letvak, L.; Larson, R. A. Fiveyear follow-up of patients receiving imatinib for chronic myeloid leukemia. N. Engl. J. Med. 2006, 355, 2408-2417.
46. Cross, N. C.; Melo, J. V.; Feng, L.; Goldman, J. M. An optimized multiplex polymerase chain reaction (PCR) for detection of BCR- ABl Fusion MRNAs in haematological disorders. Leukemia 1994, 8, 186-189.
47. Emig, M.; Saussele, S.; Wittor, H.; Weisser, A.; Reiter, A.; Willer, A.; Berger, U.; Hehlmann, R.; Cross, N. C.; Hochhaus, A. Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCR. Leukemia 1999, 13, 1825-1832.
48. Merx, K.; Müller, M. C.; Kreil, S.; Lahaye, T.; Paschka, P.; Schoch, C.; Weisser, A.; Kuhn, C.; Berger, U.; Gschaidmeier, H.; Hehlmann, R.; Hochhaus, A. Early reduction of BCR-ABL MRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha. Leukemia 2002, 16, 1579-1583.
49. Paschka, P.; Merx, K.; Hochhaus, A. Molecular surveillance of chronic myeloid leukemia patients in the imatinib era - evaluation of response and resistance. Acta Haematol. 2004, 112, 85-92.
50. Wang, L.; Pearson, K.; Ferguson, J. E.; Clark, R. E. The early molecular response to imatinib predicts cytogenetic and clinical outcome in chronic myeloid leukaemia. Br. J. Haematol. 2003, 120, 990-999.
51. Hughes, T. P.; Kaeda, J.; Branford, S.; Rudzki, Z.; Hochhaus, A.; Hensley, M. L.; Gathmann, I.; Bolton, A. E.; van Hoomissen, I. C.; Goldman, J. M.; Radich, J. P. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N. Engl. J. Med. 2003, 349, 1423-1432.
52. Eder, M.; Battmer, K.; Kafert, S.; Stucki, A.; Ganser, A.; Hertenstein, B. Monitoring of BCR-ABL expression using real-time RT-PCR in CML after bone marrow or peripheral blood stem cell transplantation. Leukemia 1999, 13, 1383-1389.
53. Elmaagacli, A. H. Real-time PCR for monitoring minimal residual disease and chimerism in patients after allogeneic transplantation. Int. J. Hematol. 2002, 76 Suppl 2, 204-205.
54. Branford, S.; Rudzki, Z.; Parkinson, I.; Grigg, A.; Taylor, K.; Seymour, J. F.; Durrant, S.; Browett, P.; Schwarer, A. P.; Arthur, C.; Catalano, J.; Leahy, M. F.; Filshie, R.; Bradstock, K.; Herrmann, R.; Joske, D.; Lynch, K.; Hughes, T. Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations. Blood 2004, 104, 2926-2932.
55. Press, R. D.; Galderisi, C.; Yang, R.; Rempfer, C.; Willis, S. G.; Mauro, M. J.; Druker, B. J.; Deininger, M. W. A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response. Clin. Cancer Res. 2007, 13, 6136-6143.
56. Wang, L.; Knight, K.; Lucas, C.; Clark, R. E. The role of serial BCR-ABL transcript monitoring in predicting the emergence of BCR-ABL kinase mutations in imatinib-treated patients with chronic myeloid leukemia. Haematologica 2006, 91, 235-239.
57. Hughes, T.; Branford, S. Molecular monitoring of BCR-ABL as a guide to clinical management in chronic myeloid leukaemia. Blood Rev. 2006, 20, 29-41.
58. Hughes, T.; Deininger, M.; Hochhaus, A.; Branford, S.; Radich, J.; Kaeda, J.; Baccarani, M.; Cortes, J.; Cross, N. C.; Druker, B. J.; Gabert, J.; Grimwade, D.; Hehlmann, R.; Kamel-Reid, S.; Lipton, J. H.; Longtine, J.; Martinelli, G.; Saglio, G.; Soverini, S.; Stock, W.; Goldman, J. M. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006, 108, 28-37.
59. Müller, M. C.; Erben, P.; Saglio, G.; Gottardi, E.; Nyvold, C. G.; Schenk, T.; Ernst, T.; Lauber, S.; Kruth, J.; Hehlmann, R.; Hochhaus, A. Harmonization of BCR-ABL MRNA quantification using a uniform multifunctional control plasmid in 37 international laboratories. Leukemia 2008, 22, 96-102.
60. Müller, M. C.; Cross, N. C.; Erben, P.; Schenk, T.; Hanfstein, B.; Ernst, T.; Hehlmann, R.; Branford, S.; Saglio, G.; Hochhaus, A. Harmonization of molecular monitoring of CML therapy in Europe. Leukemia 2009, 23, 1957-1963.
61. Singh, N.; Kumar, L.; Meena, R.; Velpandian, T. Drug monitoring of imatinib levels in patients undergoing therapy for chronic myeloid leukaemia: comparing plasma levels of responders and non-responders. Eur. J. Clin. Pharmacol. 2009, 65, 545-549.
62. Picard, S.; Titier, K.; Etienne, G.; Teilhet, E.; Ducint, D.; Bernard, M. A.; Lassalle, R.; Marit, G.; Reiffers, J.; Begaud, B.; Moore, N.; Molimard, M.; Mahon, F. X. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 2007, 109, 3496-3499.
63. Larson, R. A.; Druker, B. J.; Guilhot, F.; O'Brien, S. G.; Riviere, G. J.; Krahnke, T.; Gathmann, I.; Wang, Y. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood 2008, 111, 4022-4028.
64. Illmer, T.; Schaich, M.; Platzbecker, U.; Freiberg-Richter, J.; Oelschlagel, U.; von Bonin, M.; Pursche, S.; Bergemann, T.; Ehninger, G.; Schleyer, E. P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate. Leukemia 2004, 18, 401-408.
65. Thomas, J.; Wang, L.; Clark, R. E.; Pirmohamed, M. Active transport of imatinib into and out of cells: implications for drug resistance. Blood 2004, 104, 3739-3745.
66. White, D. L.; Saunders, V. A.; Dang, P.; Engler, J.; Zannettino, A. C.; Cambareri, A. C.; Quinn, S. R.; Manley, P. W.; Hughes, T. P. OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood 2006, 108, 697-704.
67. Hasford, J.; Pfirrmann, M.; Hehlmann, R.; Allan, N. C.; Baccarani, M.; Kluin-Nelemans, J. C.; Alimena, G.; Steegmann, J. L.; Ansari, H. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing committee for the collaborative CML prognostic factors project group. J. Natl. Cancer Inst. 1998, 90, 850-858.
68. Hochhaus, A.; O'Brien, S. G.; Guilhot, F.; Druker, B. J.; Branford, S.; Foroni, L.; Goldman, J. M.; Muller, M. C.; Radich, J. P.; Rudoltz, M.; Mone, M.; Gathmann, I.; Hughes, T. P.; Larson, R. A. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 2009, 23, 1054-1061.
69. Lowenthal, R. M.; Buskard, N. A.; Goldman, J. M.; Spiers, A. S.; Bergier, N.; Graubner, M.; Galton, D. A. Intensive leukapheresis as initial therapy for chronic granulocytic leukemia. Blood 1975, 46, 835-844.
70. Fitzgerald, D.; Rowe, J. M.; Heal, J. Leukapheresis for control of chronic myelogenous leukemia during pregnancy. Am. J. Hematol. 1986, 22, 213-218.
71. Bolin, R. W.; Robinson, W. A.; Sutherland, J.; Hamman, R. F. Busulfan versus hydroxyurea in long-term therapy of chronic myelogenous leukemia. Cancer 1982, 50, 1683-1686.
72. Williams, C. K.; Svet-Moldavskaya, I.; Vilcek, J.; Ohnuma, T.; Holland, J. F. Inhibitory effects of human leukocyte and fibroblast interferons on normal and chronic myelogenous leukemic granulocytic progenitor cells. Oncology 1981, 38, 356-360.
73. Hill, N. O.; Pardue, A.; Kahn, A.; Aleman, D.; Hill, J. M. Highdose human leukocyte interferon trials in leukemia and cancer. Med. Pediatr. Oncol. 1981, 9, 82.
74. Guilhot, F.; Guerci, A.; Fiere, D.; Harousseau, J. L.; Maloisel, F.; Bouabdallah, R.; Guyotat, D.; Rochant, H.; Najman, A.; Nicolini, F.; Colombat, P.; Abgrall, J. F.; Ifrah, N.; Briere, J.; Bauters, F.; Navarro, M.; Morice, P.; Bordessoule, D.; Vilque, J. P.; Desablens, B.; Tertian, G.; Blanc, M.; Chastang, C.; Tanzer, J. The treatment of chronic myelogenous leukemia by interferon and cytosinearabinoside: rational and design of the french trials. French CML study group. Bone Marrow Transplant. 1996, 17 Suppl 3, S29-S31.
75. Kühr, T.; Burgstaller, S.; Apfelbeck, U.; Linkesch, W.; Seewann, H.; Fridrik, M.; Michlmayr, G.; Krieger, O.; Lutz, D.; Lin, W.; Pont, J.; Kock, L.; Abbrederis, K.; Baldinger, C.; Buder, R.; Geissler, D.; Hausmaninger, H.; Lang, A.; Zabernigg, A.; Duba, C.; Hilbe, W.; Eisterer, W.; Fiegl, M.; Greil, R.; Gastl, G.; Thaler, J. A randomized study comparing interferon (IFN Alpha) plus low-dose cytarabine and interferon plus hydroxyurea (HU) in early chronicphase chronic myeloid leukemia (CML). Leuk. Res. 2003, 27, 405-411.
76. Hehlmann, R.; Berger, U.; Pfirrmann, M.; Hochhaus, A.; Metzgeroth, G.; Maywald, O.; Hasford, J.; Reiter, A.; Hossfeld, D. K.; Kolb, H. J.; Loffler, H.; Pralle, H.; Queisser, W.; Griesshammer, M.; Nerl, C.; Kuse, R.; Tobler, A.; Eimermacher, H.; Tichelli, A.; Aul, C.; Wilhelm, M.; Fischer, J. T.; Perker, M.; Scheid, C.; Schenk, M.; Weiss, J.; Meier, C. R.; Kremers, S.; Labedzki, L.; Schmeiser, T.; Lohrmann, H. P.; Heimpel, H. Randomized comparison of interferon alpha and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-Study II): Prolongation of survival by the combination of interferon alpha and hydroxyurea. Leukemia 2003, 17, 1529-1537.
77. Interferon alfa versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials: Chronic myeloid leukemia trialists' collaborative group. J. Natl. Cancer Inst. 1997, 89, 1616-1620.
78. Bonifazi, F.; de Vivo, A.; Rosti, G.; Guilhot, F.; Guilhot, J.; Trabacchi, E.; Hehlmann, R.; Hochhaus, A.; Shepherd, P. C.; Steegmann, J. L.; Kluin-Nelemans, H. C.; Thaler, J.; Simonsson, B.; Louwagie, A.; Reiffers, J.; Mahon, F. X.; Montefusco, E.; Alimena, G.; Hasford, J.; Richards, S.; Saglio, G.; Testoni, N.; Martinelli, G.; Tura, S.; Baccarani, M. Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders. Blood 2001, 98, 3074-3081.
79. Kantarjian, H. M.; O'Brien, S.; Cortes, J. E.; Shan, J.; Giles, F. J.; Rios, M. B.; Faderl, S. H.; Wierda, W. G.; Ferrajoli, A.; Verstovsek, S.; Keating, M. J.; Freireich, E. J.; Talpaz, M. Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis. Cancer 2003, 97, 1033-1041.
80. Michallet, M.; Maloisel, F.; Delain, M.; Hellmann, A.; Rosas, A.; Silver, R. T.; Tendler, C. Pegylated recombinant interferon alpha-2b vs recombinant interferon alpha-2b for the initial treatment of chronic-phase chronic myelogenous leukemia: a phase III study. Leukemia 2004, 18, 309-315.
81. Lipton, J. H.; Khoroshko, N.; Golenkov, A.; Abdulkadyrov, K.; Nair, K.; Raghunadharao, D.; Brummendorf, T.; Yoo, K.; Bergstrom, B. Phase II, randomized, multicenter, comparative study of peginterferon-alpha-2a (40 KD) (Pegasys) versus interferon alpha- 2a (Roferon-A) in patients with treatment-naive, chronic-phase chronic myelogenous leukemia. Leuk. Lymphoma 2007, 48, 497-505.
82. Burchert, A.; Wolfl, S.; Schmidt, M.; Brendel, C.; Denecke, B.; Cai, D.; Odyvanova, L.; Lahaye, T.; Müller, M. C.; Berg, T.; Gschaidmeier, H.; Wittig, B.; Hehlmann, R.; Hochhaus, A.; Neubauer, A. Interferon-alpha, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific t-cell response in chronic myeloid leukemia. Blood 2003, 101, 259-264.
83. Molldrem, J. J.; Dermime, S.; Parker, K.; Jiang, Y. Z.; Mavroudis, D.; Hensel, N.; Fukushima, P.; Barrett, A. J. Targeted T-cell therapy for human leukemia: cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells. Blood 1996, 88, 2450-2457.
84. Essers, M. A.; Offner, S.; Blanco-Bose, W. E.; Waibler, Z.; Kalinke, U.; Duchosal, M. A.; Trumpp, A. IFNalpha activates dormant haematopoietic stem cells in vivo. Nature 2009, 458, 904-908.
85. Sato, T.; Onai, N.; Yoshihara, H.; Arai, F.; Suda, T.; Ohteki, T. Interferon regulatory factor-2 protects quiescent hematopoietic stem cells from type I interferon-dependent exhaustion. Nat. Med. 2009, 15, 696-700.
86. Passegue, E.; Ernst, P. IFN-alpha wakes up sleeping hematopoietic stem cells. Nat. Med. 2009, 15, 612-613.
87. Panzica, R. P.; Robins, R. K.; Townsend, L. B. Synthesis and anticancer activity of cytosine arabinoside 3-N-oxide (Ara-C 3-N- Oxide). J. Med. Chem. 1971, 14, 259-260.
88. Sokal, J. E.; Gockerman, J. P.; Bigner, S. H. Evidence for a selective antileukemic effect of cytosine arabinoside in chronic granulocytic leukemia. Leuk. Res. 1988, 12, 453-458.
89. Buchdunger, E.; Zimmermann, J.; Mett, H.; Meyer, T.; Muller, M.; Regenass, U.; Lydon, N. B. Selective inhibition of the platelet-derived growth factor signal transduction pathway by a proteintyrosine kinase inhibitor of the 2-phenylaminopyrimidine class. Proc. Natl. Acad. Sci. U. S. A 1995, 92, 2558-2562.
90. Buchdunger, E.; Zimmermann, J.; Mett, H.; Meyer, T.; Muller, M.; Druker, B. J.; Lydon, N. B. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res. 1996, 56, 100-104.
91. Schindler, T.; Bornmann, W.; Pellicena, P.; Miller, W. T.; Clarkson, B.; Kuriyan, J. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 2000, 289, 1938-1942.
92. Druker, B. J.; Talpaz, M.; Resta, D. J.; Peng, B.; Buchdunger, E.; Ford, J. M.; Lydon, N. B.; Kantarjian, H.; Capdeville, R.; Ohno-Jones, S.; Sawyers, C. L. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 2001, 344, 1031-1037.
93. Kantarjian, H.; Sawyers, C.; Hochhaus, A.; Guilhot, F.; Schiffer, C.; Gambacorti-Passerini, C.; Niederwieser, D.; Resta, D.; Capdeville, R.; Zoellner, U.; Talpaz, M.; Druker, B. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N. Engl. J. Med. 2002, 346, 645-652.
94. Cohen, M. H.; Williams, G.; Johnson, J. R.; Duan, J.; Gobburu, J.; Rahman, A.; Benson, K.; Leighton, J.; Kim, S. K.; Wood, R.; Rothmann, M.; Chen, G.; KM, U.; Staten, A. M.; Pazdur, R. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin. Cancer Res. 2002, 8, 935-942.
95. Kantarjian, H. M.; O'Brien, S.; Cortes, J. E.; Smith, T. L.; Rios, M. B.; Shan, J.; Yang, Y.; Giles, F. J.; Thomas, D. A.; Faderl, S.; Garcia-Manero, G.; Jeha, S.; Wierda, W.; Issa, J. P.; Kornblau, S. M.; Keating, M.; Resta, D.; Capdeville, R.; Talpaz, M. Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate. Clin. Cancer Res. 2002, 8, 2167-2176.
96. Johnson, J. R.; Bross, P.; Cohen, M.; Rothmann, M.; Chen, G.; Zajicek, A.; Gobburu, J.; Rahman, A.; Staten, A.; Pazdur, R. Approval summary: imatinib mesylate capsules for treatment of adult patients with newly diagnosed philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase. Clin. Cancer Res. 2003, 9, 1972-1979.
97. O'Brien, S. G.; Guilhot, F.; Larson, R. A.; Gathmann, I.; Baccarani, M.; Cervantes, F.; Cornelissen, J. J.; Fischer, T.; Hochhaus, A.; Hughes, T.; Lechner, K.; Nielsen, J. L.; Rousselot, P.; Reiffers, J.; Saglio, G.; Shepherd, J.; Simonsson, B.; Gratwohl, A.; Goldman, J. M.; Kantarjian, H.; Taylor, K.; Verhoef, G.; Bolton, A. E.; Capdeville, R.; Druker, B. J. Imatinib compared with interferon and lowdose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med. 2003, 348, 994-1004.
98. Hasford, J.; Pfirrmann, M.; Hochhaus, A. How long will chronic myeloid leukemia patients treated with imatinib mesylate live? Leukemia 2005, 19, 497-499.
99. Guilhot, F.; Druker, B.; Larson, R. A.; Gathmann, I.; So, C.; Waltzman, R.; O'Brien, S. G. High rates of durable response are achieved with imatinib after treatment with interferon {alpha} plus cytarabine: results from the international randomized study of interferon and STI571 (IRIS) trial. Haematologica 2009, 94, 1669-1675.
100. Rousselot, P.; Huguet, F.; Rea, D.; Legros, L.; Cayuela, J. M.; Maarek, O.; Blanchet, O.; Marit, G.; Gluckman, E.; Reiffers, J.; Gardembas, M.; Mahon, F. X. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 2007, 109, 58-60.
101. Burchert, A.; Müller, M. C.; Kostrewa, P.; Erben, P.; Bostel, T.; Liebler, S.; Hehlmann, R.; Neubauer, A.; Hochhaus, A. Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia. J. Clin. Oncol. 2010, 28, 1429-1435.
102. Talpaz, M.; Silver, R. T.; Druker, B. J.; Goldman, J. M.; Gambacorti-Passerini, C.; Guilhot, F.; Schiffer, C. A.; Fischer, T.; Deininger, M. W.; Lennard, A. L.; Hochhaus, A.; Ottmann, O. G.; Gratwohl, A.; Baccarani, M.; Stone, R.; Tura, S.; Mahon, F. X.; Fernandes-Reese, S.; Gathmann, I.; Capdeville, R.; Kantarjian, H. M.; Sawyers, C. L. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002, 99, 1928-1937.
103. Sawyers, C. L.; Hochhaus, A.; Feldman, E.; Goldman, J. M.; Miller, C. B.; Ottmann, O. G.; Schiffer, C. A.; Talpaz, M.; Guilhot, F.; Deininger, M. W.; Fischer, T.; O'Brien, S. G.; Stone, R. M.; Gambacorti-Passerini, C. B.; Russell, N. H.; Reiffers, J. J.; Shea, T. C.; Chapuis, B.; Coutre, S.; Tura, S.; Morra, E.; Larson, R. A.; Saven, A.; Peschel, C.; Gratwohl, A.; Mandelli, F.; Ben Am, M.; Gathmann, I.; Capdeville, R.; Paquette, R. L.; Druker, B. J. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 2002, 99, 3530-3539.
104. Hochhaus, A.; Kreil, S.; Corbin, A. S.; La Rosee, P.; Müller, M. C.; Lahaye, T.; Hanfstein, B.; Schoch, C.; Cross, N. C.; Berger, U.; Gschaidmeier, H.; Druker, B. J.; Hehlmann, R. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 2002, 16, 2190-2196.
105. le Coutre, P.; Tassi, E.; Varella-Garcia, M.; Barni, R.; Mologni, L.; Cabrita, G.; Marchesi, E.; Supino, R.; Gambacorti-Passerini, C. Induction of resistance to the abelson inhibitor sti571 in human leukemic cells through gene amplification. Blood 2000, 95, 1758-1766.
106. Gorre, M. E.; Mohammed, M.; Ellwood, K.; Hsu, N.; Paquette, R.; Rao, P. N.; Sawyers, C. L. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001, 293, 876-880.
107. Bumm, T.; Muller, C.; Al Ali, H. K.; Krohn, K.; Shepherd, P.; Schmidt, E.; Leiblein, S.; Franke, C.; Hennig, E.; Friedrich, T.; Krahl, R.; Niederwieser, D.; Deininger, M. W. Emergence of clonal cytogenetic abnormalities in Phcells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority. Blood 2003, 101, 1941-1949.
108. O'Dwyer, M. E.; Mauro, M. J.; Blasdel, C.; Farnsworth, M.; Kurilik, G.; Hsieh, Y. C.; Mori, M.; Druker, B. J. Clonal evolution and lack of cytogenetic response are adverse prognostic factors for hematologic relapse of chronic phase CML patients treated with imatinib mesylate. Blood 2004, 103, 451-455.
109. Bacher, U.; Haferlach, T.; Hiddemann, W.; Schnittger, S.; Kern, W.; Schoch, C. Additional clonal abnormalities in philadelphiapositive ALL and CML demonstrate a different cytogenetic pattern at diagnosis and follow different pathways at progression. Cancer Genet. Cytogenet. 2005, 157, 53-61.
110. Loriaux, M.; Deininger, M. Clonal cytogenetic abnormalities in philadelphia chromosome negative cells in chronic myeloid leukemia patients treated with imatinib. Leuk. Lymphoma 2004, 45, 2197-2203.
111. Donato, N. J.; Wu, J. Y.; Stapley, J.; Gallick, G.; Lin, H.; Arlinghaus, R.; Talpaz, M. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 2003, 101, 690-698.
112. Crossman, L. C.; Druker, B. J.; Deininger, M. W.; Pirmohamed, M.; Wang, L.; Clark, R. E. HOCT 1 and resistance to imatinib. Blood 2005, 106, 1133-1134.
113. Ricci, C.; Scappini, B.; Divoky, V.; Gatto, S.; Onida, F.; Verstovsek, S.; Kantarjian, H. M.; Beran, M. Mutation in the ATP- binding pocket of the ABL kinase domain in an STI571-resistant BCR/ABL-positive cell line. Cancer Res. 2002, 62, 5995-5998.
114. Allen, P. B.; Wiedemann, L. M. An activating mutation in the ATP binding site of the ABL kinase domain. J. Biol. Chem. 1996, 271, 19585-19591.
115. Roumiantsev, S.; Shah, N. P.; Gorre, M. E.; Nicoll, J.; Brasher, B. B.; Sawyers, C. L.; Van Etten, R. A. Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop. Proc. Natl. Acad. Sci. U. S. A 2002, 99, 10700-10705.
116. Barthe, C.; Gharbi, M. J.; Lagarde, V.; Chollet, C.; Cony-Makhoul, P.; Reiffers, J.; Goldman, J. M.; Melo, J. V.; Mahon, F. X. Mutation in the ATP-binding site of BCR-ABL in a patient with chronic myeloid leukaemia with increasing resistance to STI571. Br. J. Haematol. 2002, 119, 109-111.
117. Khorashad, J. S.; de Lavallade, H.; Apperley, J. F.; Milojkovic, D.; Reid, A. G.; Bua, M.; Szydlo, R.; Olavarria, E.; Kaeda, J.; Goldman, J. M.; Marin, D. Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression. J. Clin. Oncol. 2008, 26, 4806-4813.
118. Willis, S. G.; Lange, T.; Demehri, S.; Otto, S.; Crossman, L.; Niederwieser, D.; Stoffregen, E. P.; McWeeney, S.; Kovacs, I.; Park, B.; Druker, B. J.; Deininger, M. W. High-sensitivity detection of BCR- ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy. Blood 2005, 106, 2128-2137.
119. Ernst, T.; Hoffmann, J.; Erben, P.; Hanfstein, B.; Leitner, A.; Hehlmann, R.; Hochhaus, A.; Müller, M. C. ABL single nucleotide polymorphisms may masquerade as BCR-ABL mutations associated with resistance to tyrosine kinase inhibitors in CML patients. Haematologica 2008, 93, 1389-1393.
120. Baccarani, M.; Rosti, G.; Castagnetti, F.; Haznedaroglu, I.; Porkka, K.; Abruzzese, E.; Alimena, G.; Ehrencrona, H.; Hjorth-Hansen, H.; Kairisto, V.; Levato, L.; Martinelli, G.; Nagler, A.; Lanng, N. J.; Ozbek, U.; Palandri, F.; Palmieri, F.; Pane, F.; Rege-Cambrin, G.; Russo, D.; Specchia, G.; Testoni, N.; Weiss-Bjerrum, O.; Saglio, G.; Simonsson, B. Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, philadelphiapositive chronic myeloid leukemia: a european leukemianet study. Blood 2009, 113, 4497-4504.
121. Weisberg, E.; Manley, P. W.; Breitenstein, W.; Bruggen, J.; Cowan-Jacob, S. W.; Ray, A.; Huntly, B.; Fabbro, D.; Fendrich, G.; Hall-Meyers, E.; Kung, A. L.; Mestan, J.; Daley, G. Q.; Callahan, L.; Catley, L.; Cavazza, C.; Azam, M.; Neuberg, D.; Wright, R. D.; Gilliland, D. G.; Griffin, J. D. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005, 7, 129-141.
122. Weisberg, E.; Manley, P.; Mestan, J.; Cowan-Jacob, S.; Ray, A.; Griffin, J. D. AMN107 (Nilotinib): a novel and selective inhibitor of BCR-ABL. Br. J. Cancer 2006, 94, 1765-1769.
123. Kantarjian, H. M.; Giles, F.; Gattermann, N.; Bhalla, K.; Alimena, G.; Palandri, F.; Ossenkoppele, G. J.; Nicolini, F. E.; O'Brien, S. G.; Litzow, M.; Bhatia, R.; Cervantes, F.; Haque, A.; Shou, Y.; Resta, D. J.; Weitzman, A.; Hochhaus, A.; le Coutre, P. Nilotinib (Formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 2007, 110, 3540-3546.
124. le Coutre, P.; Ottmann, O. G.; Giles, F.; Kim, D. W.; Cortes, J.; Gattermann, N.; Apperley, J. F.; Larson, R. A.; Abruzzese, E.; O'Brien, S. G.; Kuliczkowski, K.; Hochhaus, A.; Mahon, F. X.; Saglio, G.; Gobbi, M.; Kwong, Y. L.; Baccarani, M.; Hughes, T.; Martinelli, G.; Radich, J. P.; Zheng, M.; Shou, Y.; Kantarjian, H. Nilotinib (Formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. Blood 2008, 111, 1834-1839.
125. Kantarjian, H.; Giles, F.; Wunderle, L.; Bhalla, K.; O'Brien, S.; Wassmann, B.; Tanaka, C.; Manley, P.; Rae, P.; Mietlowski, W.; Bochinski, K.; Hochhaus, A.; Griffin, J. D.; Hoelzer, D.; Albitar, M.; Dugan, M.; Cortes, J.; Alland, L.; Ottmann, O. G. Nilotinib in imatinib-resistant CML and philadelphia chromosome-positive ALL. N. Engl. J. Med. 2006, 354, 2542-2551.
126. Deininger, M. W. Nilotinib. Clin. Cancer Res. 2008, 14, 4027-4031.
127. Hughes, T.; Saglio, G.; Branford, S.; Soverini, S.; Kim, D. W.; Muller, M. C.; Martinelli, G.; Cortes, J.; Beppu, L.; Gottardi, E.; Kim, D.; Erben, P.; Shou, Y.; Haque, A.; Gallagher, N.; Radich, J.; Hochhaus, A. Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase. J. Clin. Oncol. 2009, 27, 4204-4210.
128. Saglio, G.; Kim, D. W.; Issaragrisil, S.; le Coutre, P.; Etienne, G.; Lobo, C.; Pasquini, R.; Clark, R. E.; Hochhaus, A.; Hughes, T. P.; Gallagher, N.; Hoenekopp, A.; Dong, M.; Haque, A.; Larson, R. A.; Kantarjian, H. M. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N. Engl. J. Med. 2010, 362, 2251-2259.
129. Tokarski, J. S.; Newitt, J. A.; Chang, C. Y.; Cheng, J. D.; Wittekind, M.; Kiefer, S. E.; Kish, K.; Lee, F. Y.; Borzillerri, R.; Lombardo, L. J.; Xie, D.; Zhang, Y.; Klei, H. E. The structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res. 2006, 66, 5790-5797.
130. Konig, H.; Copland, M.; Chu, S.; Jove, R.; Holyoake, T. L.; Bhatia, R. Effects of dasatinib on SRC kinase activity and downstream intracellular signaling in primitive chronic myelogenous leukemia hematopoietic cells. Cancer Res. 2008, 68, 9624-9633.
131. Donato, N. J.; Wu, J. Y.; Stapley, J.; Lin, H.; Arlinghaus, R.; Aggarwal, B. B.; Shishodia, S.; Albitar, M.; Hayes, K.; Kantarjian, H.; Talpaz, M. imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia. Cancer Res. 2004, 64, 672-677.
132. Hochhaus, A.; Baccarani, M.; Deininger, M.; Apperley, J. F.; Lipton, J. H.; Goldberg, S. L.; Corm, S.; Shah, N. P.; Cervantes, F.; Silver, R. T.; Niederwieser, D.; Stone, R. M.; Dombret, H.; Larson, R. A.; Roy, L.; Hughes, T.; Müller, M. C.; Ezzeddine, R.; Countouriotis, A. M.; Kantarjian, H. M. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia 2008, 22, 1200-1206.
133. Hochhaus, A.; Kantarjian, H. M.; Baccarani, M.; Lipton, J. H.; Apperley, J. F.; Druker, B. J.; Facon, T.; Goldberg, S. L.; Cervantes, F.; Niederwieser, D.; Silver, R. T.; Stone, R. M.; Hughes, T. P.; Müller, M. C.; Ezzeddine, R.; Countouriotis, A. M.; Shah, N. P. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood 2007, 109, 2303-2309.
134. Guilhot, F.; Apperley, J.; Kim, D. W.; Bullorsky, E. O.; Baccarani, M.; Roboz, G. J.; Amadori, S.; de Souza, C. A.; Lipton, J. H.; Hochhaus, A.; Heim, D.; Larson, R. A.; Branford, S.; Müller, M. C.; Agarwal, P.; Gollerkeri, A.; Talpaz, M. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood 2007, 109, 4143-4150.
135. Cortes, J.; Rousselot, P.; Kim, D. W.; Ritchie, E.; Hamerschlak, N.; Coutre, S.; Hochhaus, A.; Guilhot, F.; Saglio, G.; Apperley, J.; Ottmann, O.; Shah, N.; Erben, P.; Branford, S.; Agarwal, P.; Gollerkeri, A.; Baccarani, M. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood 2007, 109, 3207-3213.
136. Cortes, J.; Kim, D. W.; Raffoux, E.; Martinelli, G.; Ritchie, E.; Roy, L.; Coutre, S.; Corm, S.; Hamerschlak, N.; Tang, J. L.; Hochhaus, A.; Khoury, H. J.; Brummendorf, T. H.; Michallet, M.; Rege-Cambrin, G.; Gambacorti-Passerini, C.; Radich, J. P.; Ernst, T.; Zhu, C.; Van Tornout, J. M.; Talpaz, M. Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase. Leukemia 2008, 22, 2176-2183.
137. Ottmann, O.; Dombret, H.; Martinelli, G.; Simonsson, B.; Guilhot, F.; Larson, R. A.; Rege-Cambrin, G.; Radich, J.; Hochhaus, A.; Apanovitch, A. M.; Gollerkeri, A.; Coutre, S. Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study. Blood 2007, 110, 2309-2315.
138. Kantarjian, H.; Pasquini, R.; Hamerschlak, N.; Rousselot, P.; Holowiecki, J.; Jootar, S.; Robak, T.; Khoroshko, N.; Masszi, T.; Skotnicki, A.; Hellmann, A.; Zaritsky, A.; Golenkov, A.; Radich, J.; Hughes, T.; Countouriotis, A.; Shah, N. Dasatinib or High-Dose Imatinib for Chronic-Phase Chronic Myeloid Leukemia After Failure of First-Line Imatinib: a Randomized Phase 2 Trial. Blood 2007, 109, 5143-5150.
139. Shah, N. P.; Kantarjian, H. M.; Kim, D. W.; Rea, D.; Dorlhiac-Llacer, P. E.; Milone, J. H.; Vela-Ojeda, J.; Silver, R. T.; Khoury, H. J.; Charbonnier, A.; Khoroshko, N.; Paquette, R. L.; Deininger, M.; Collins, R. H.; Otero, I.; Hughes, T.; Bleickardt, E.; Strauss, L.; Francis, S.; Hochhaus, A. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J. Clin. Oncol. 2008, 26, 3204-3212.
140. Brave, M.; Goodman, V.; Kaminskas, E.; Farrell, A.; Timmer, W.; Pope, S.; Harapanhalli, R.; Saber, H.; Morse, D.; Bullock, J.; Men, A.; Noory, C.; Ramchandani, R.; Kenna, L.; Booth, B.; Gobburu, J.; Jiang, X.; Sridhara, R.; Justice, R.; Pazdur, R. Sprycel for chronic myeloid leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate. Clin. Cancer Res. 2008, 14, 352-359.
141. Talpaz, M.; Shah, N. P.; Kantarjian, H.; Donato, N.; Nicoll, J.; Paquette, R.; Cortes, J.; O'Brien, S.; Nicaise, C.; Bleickardt, E.; Blackwood-Chirchir, M. A.; Iyer, V.; Chen, T. T.; Huang, F.; Decillis, A. P.; Sawyers, C. L. Dasatinib in imatinib-resistant philadelphia chromosome-positive leukemias. N. Engl. J. Med. 2006, 354, 2531-2541.
142. Soverini, S.; Colarossi, S.; Gnani, A.; Castagnetti, F.; Rosti, G.; Bosi, C.; Paolini, S.; Rondoni, M.; Piccaluga, P. P.; Palandri, F.; Giannoulia, P.; Marzocchi, G.; Luatti, S.; Testoni, N.; Iacobucci, I.; Cilloni, D.; Saglio, G.; Baccarani, M.; Martinelli, G. Resistance to dasatinib in philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain. Haematologica 2007, 92, 401-404.
143. Shah, N. P.; Skaggs, B. J.; Branford, S.; Hughes, T. P.; Nicoll, J. M.; Paquette, R. L.; Sawyers, C. L. Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. J. Clin. Invest. 2007, 117, 2562-2569.
144. Cortes, J.; Jabbour, E.; Kantarjian, H.; Yin, C. C.; Shan, J.; O'Brien, S.; Garcia-Manero, G.; Giles, F.; Breeden, M.; Reeves, N.; Wierda, W. G.; Jones, D. Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors. Blood 2007, 110, 4005-4011.
145. Müller, M. C.; Cortes, J. E.; Kim, D. W.; Druker, B. J.; Erben, P.; Pasquini, R.; Branford, S.; Hughes, T. P.; Radich, J. P.; Ploughman, L.; Mukhopadhyay, J.; Hochhaus, A. Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations. Blood 2009, 114, 4944-4953.
146. Dai, H.; Marbach, P.; Lemaire, M.; Hayes, M.; Elmquist, W. F. Distribution of STI-571 to the brain is limited by p-glycoproteinmediated efflux. J. Pharmacol. Exp. Ther. 2003, 304, 1085-1092.
147. Breedveld, P.; Pluim, D.; Cipriani, G.; Wielinga, P.; van Tellingen, O.; Schinkel, A. H.; Schellens, J. H. The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and p-glycoprotein inhibitors to enable the brain penetration of imatinib in patients. Cancer Res. 2005, 65, 2577-2582.
148. Lagas, J. S.; van Waterschoot, R. A.; van Tilburg, V. A.; Hillebrand, M. J.; Lankheet, N.; Rosing, H.; Beijnen, J. H.; Schinkel, A. H. Brain accumulation of dasatinib is restricted by p-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by elacridar treatment. Clin. Cancer Res. 2009, 15, 2344-2351.
149. Chen, Y.; Agarwal, S.; Shaik, N. M.; Chen, C.; Yang, Z.; Elmquist, W. F. P-glycoprotein and breast cancer resistance protein influence brain distribution of dasatinib. J. Pharmacol. Exp. Ther. 2009, 330, 956-963.
150. Porkka, K.; Koskenvesa, P.; Lundan, T.; Rimpilainen, J.; Mustjoki, S.; Smykla, R.; Wild, R.; Luo, R.; Arnan, M.; Brethon, B.; Eccersley, L.; Hjorth-Hansen, H.; Hoglund, M.; Klamova, H.; Knutsen, H.; Parikh, S.; Raffoux, E.; Gruber, F.; Brito-Babapulle, F.; Dombret, H.; Duarte, R. F.; Elonen, E.; Paquette, R.; Zwaan, C. M.; Lee, F. Y. Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system philadelphia chromosomepositive leukemia. Blood 2008, 112, 1005-1012.
151. Kantarjian, H.; Shah, N. P.; Hochhaus, A.; Cortes, J.; Shah, S.; Ayala, M.; Moiraghi, B.; Shen, Z.; Mayer, J.; Pasquini, R.; Nakamae, H.; Huguet, F.; Boque, C.; Chuah, C.; Bleickardt, E.; Bradley-Garelik, M. B.; Zhu, C.; Szatrowski, T.; Shapiro, D.; Baccarani, M. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med. 2010, 362, 2260-2270.
152. Olavarria, E. Autologous stem cell transplantation in chronic myeloid leukemia. Semin. Hematol. 2007, 44, 252-258.
153. Hehlmann, R.; Berger, U.; Pfirrmann, M.; Heimpel, H.; Hochhaus, A.; Hasford, J.; Kolb, H. J.; Lahaye, T.; Maywald, O.; Reiter, A.; Hossfeld, D. K.; Huber, C.; Loffler, H.; Pralle, H.; Queisser, W.; Tobler, A.; Nerl, C.; Solenthaler, M.; Goebeler, M. E.; Griesshammer, M.; Fischer, T.; Kremers, S.; Eimermacher, H.; Pfreundschuh, M.; Hirschmann, W. D.; Lechner, K.; Wassmann, B.; Falge, C.; Kirchner, H. H.; Gratwohl, A. Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia. Blood 2007, 109, 4686-4692.
154. Saussele, S.; Lauseker, M.; Gratwohl, A.; Beelen, D. W.; Bunjes, D.; Schwerdtfeger, R.; Kolb, H. J.; Ho, A. D.; Falge, C.; Holler, E.; Schlimok, G.; Zander, A. R.; Arnold, R.; Kanz, L.; Dengler, R.; Haferlach, C.; Schlegelberger, B.; Pfirrmann, M.; Müller, M. C.; Schnittger, S.; Leitner, A.; Pletsch, N.; Hochhaus, A.; Hasford, J.; Hehlmann, R. Allogeneic hematopoietic stem cell transplantation (Allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML study IV. Blood 2010, 115, 1880-1885.
155. Jain, N.; Reuben, J. M.; Kantarjian, H.; Li, C.; Gao, H.; Lee, B. N.; Cohen, E. N.; Ebarb, T.; Scheinberg, D. A.; Cortes, J. Synthetic tumor-specific breakpoint peptide vaccine in patients with chronic myeloid leukemia and minimal residual disease: a phase 2 trial. Cancer 2009, 115, 3924-3934.
156. Quintas-Cardama, A.; Kantarjian, H.; O'Brien, S.; Borthakur, G.; Bruzzi, J.; Munden, R.; Cortes, J. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J. Clin. Oncol. 2007, 25, 3908-3914.
157. Giles, F. J.; O'Dwyer, M.; Swords, R. Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. Leukemia 2009, 23, 1698-1707.
158. Palandri, F.; Castagnetti, F.; Soverini, S.; Poerio, A.; Gugliotta, G.; Luatti, S.; Amabile, M.; Martinelli, G.; Rosti, G.; Baccarani, M. Pancreatic enzyme elevation in chronic myeloid leukemia patients treated with nilotinib after imatinib failure. Haematologica 2009, 94, 1758-1761.